207 related articles for article (PubMed ID: 33755341)
21. Histogenetic phenotypes of B cells in posttransplant lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type: solid organ vs hematopoietic stem cell transplantation.
Novoa-Takara L; Perkins SL; Qi D; Shidham VB; Vesole DH; Hariharan S; Luo Y; Ewton A; Chang CC
Am J Clin Pathol; 2005 Jan; 123(1):104-12. PubMed ID: 15762285
[TBL] [Abstract][Full Text] [Related]
22. Presentation and outcomes of post-transplant lymphoproliferative disorder at a single institution pediatric transplant center.
Ramos-Gonzalez G; Crum R; Allain A; Agur T; O'Melia L; Staffa S; Burchett SK; Siegele B; Weinberg O; Rodig NM; Fawaz R; Singh TP; Freiberger DA; Bae Kim H
Pediatr Transplant; 2022 Aug; 26(5):e14268. PubMed ID: 35304794
[TBL] [Abstract][Full Text] [Related]
23. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
[TBL] [Abstract][Full Text] [Related]
24. Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders.
Sarkozy C; Kaltenbach S; Faurie P; Canioni D; Berger F; Traverse-Glehen A; Ghesquieres H; Salles G; Bachy E; Alyanakian MA; Hermine O; Neven B; Macintyre E; Romana S; Molina TJ; Suarez F; Asnafi V; Bruneau J
Genes Chromosomes Cancer; 2017 Mar; 56(3):221-230. PubMed ID: 27750397
[TBL] [Abstract][Full Text] [Related]
25. Post-transplantation lymphoproliferative disease in Chinese: the Queen Mary Hospital experience in Hong Kong.
Au WY; Lie AK; Kwong YL; Shek TW; Hawkins BR; Lai KN; Tang SC; Lo CM; Fan ST; Liu CL; Chan GC; Chau EM; Chiu SW; Liang R
Leuk Lymphoma; 2002 Jul; 43(7):1403-7. PubMed ID: 12389620
[TBL] [Abstract][Full Text] [Related]
26. Distinctive Clinicopathologic Features of Monomorphic B-cell Post-transplant Lymphoproliferative Disorders in Children.
Zhang Y; Mariani R; Gong M; Kirschmann D; Caparelli E; Wallace N; Turner R; Lu X; Gao J; Yap KL; Gong S
Pediatr Dev Pathol; 2021; 24(4):318-326. PubMed ID: 33872109
[TBL] [Abstract][Full Text] [Related]
27. CD30 expression and survival in posttransplant lymphoproliferative disorders.
Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
[No Abstract] [Full Text] [Related]
28. [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
Xu LP; Huang XJ; Liu DH; Chen YH; Shi HX; Chen DB
Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):996-9. PubMed ID: 18478915
[TBL] [Abstract][Full Text] [Related]
29. Single-center analysis of biopsy-confirmed posttransplant lymphoproliferative disorder: incidence, clinicopathological characteristics and prognostic factors.
Dierickx D; Tousseyn T; Sagaert X; Fieuws S; Wlodarska I; Morscio J; Brepoels L; Kuypers D; Vanhaecke J; Nevens F; Verleden G; Van Damme-Lombaerts R; Renard M; Pirenne J; De Wolf-Peeters C; Verhoef G
Leuk Lymphoma; 2013 Nov; 54(11):2433-40. PubMed ID: 23442063
[TBL] [Abstract][Full Text] [Related]
30. Post-transplantation lymphoproliferative disease in pediatric liver recipients in Taiwan.
Hsu CT; Chang MH; Ho MC; Chang HH; Lu MY; Jou ST; Ni YH; Chen HL; Hsu HY; Wu JF
J Formos Med Assoc; 2019 Nov; 118(11):1537-1545. PubMed ID: 30630698
[TBL] [Abstract][Full Text] [Related]
31. Post-transplant lymphoproliferative disorders after live donor renal transplantation.
Jain M; Badwal S; Pandey R; Srivastava A; Sharma RK; Gupta RK
Clin Transplant; 2005 Oct; 19(5):668-73. PubMed ID: 16146560
[TBL] [Abstract][Full Text] [Related]
32. Pediatric Gastrointestinal Posttransplant Lymphoproliferative Disorder: Incidence, Clinical Characteristics, and Impact of Major Surgical Interventions Upon Overall Survival.
Dziegielewski C; Contreras R; Weitzman S; Gerstle JT
J Pediatr Hematol Oncol; 2018 Aug; 40(6):438-444. PubMed ID: 29794643
[TBL] [Abstract][Full Text] [Related]
33. Post-transplant lymphoproliferative disease in children, adolescents, and young adults.
Gross TG; Rubinstein JD
Hematol Oncol; 2023 Jun; 41 Suppl 1():48-56. PubMed ID: 37294957
[TBL] [Abstract][Full Text] [Related]
34. Post Transplant Lymphoproliferative Disorder risk factors in children: Analysis of a 23-year single-institutional experience.
Bosse RC; Franke AJ; Paul Skelton W; Woody LE; Bishnoi R; Wang Y; Bhaduri-McIntosh S; Rajderkar D; Shih R; Dang NH; Slayton WB
Pediatr Transplant; 2020 Aug; 24(5):e13747. PubMed ID: 32497335
[TBL] [Abstract][Full Text] [Related]
35. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
[TBL] [Abstract][Full Text] [Related]
36. Post‑transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012.
Marinho-Dias J; Lobo J; Henrique R; Baldaque I; Pinho-Vaz C; Regadas L; Branca R; Campilho F; Campos A; Medeiros R; Sousa H
Mol Med Rep; 2018 Nov; 18(5):4650-4656. PubMed ID: 30221663
[TBL] [Abstract][Full Text] [Related]
37. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
[TBL] [Abstract][Full Text] [Related]
38. Posttransplantation lymphoproliferative disorders in pediatric thoracic organ recipients.
Boyle GJ; Michaels MG; Webber SA; Knisely AS; Kurland G; Cipriani LA; Griffith BP; Fricker FJ
J Pediatr; 1997 Aug; 131(2):309-13. PubMed ID: 9290623
[TBL] [Abstract][Full Text] [Related]
39. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients.
Schober T; Framke T; Kreipe H; Schulz TF; Großhennig A; Hussein K; Baumann U; Pape L; Schubert S; Wingen AM; Jack T; Koch A; Klein C; Maecker-Kolhoff B
Transplantation; 2013 Jan; 95(1):240-6. PubMed ID: 23222898
[TBL] [Abstract][Full Text] [Related]
40. Donor or recipient origin of posttransplant lymphoproliferative disorders following solid organ transplantation.
Kinch A; Cavelier L; Bengtsson M; Baecklund E; Enblad G; Backlin C; Thunberg U; Sundström C; Pauksens K
Am J Transplant; 2014 Dec; 14(12):2838-45. PubMed ID: 25307322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
